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1. Background
Typhoid fever, a systemic illness, is caused by Salmonella Typhi
(S. Typhi), a Gram-negative bacterium [1]. Typhoid fever varies in
its clinical presentation depending on the time and stage of infection. Patients may present with mild illness of low-grade fever,
malaise, and slight dry cough. The more severe clinical presentation may include abdominal discomfort and complications such
as gastrointestinal bleeding resulting to shock. If untreated,
typhoid fever may result to intestinal perforation and in many
cases death. Factors such as duration of illness before the initiation
of appropriate therapy, the choice of antimicrobial treatment, age,
the previous exposure or vaccination history influence the severity
and overall clinical outcome of typhoid fever.
Multidrug resistant strains including extensively drug-resistant
(XDR) S. Typhi are decreasing effectiveness of lifesaving antibiotics
[2]. The XDR isolates from Pakistan showed an array of genetic modifications, conferring resistance to first-line antibiotics as well as fluoroquinolones and third generation cephalosporins. This may be
referred to as the biosocial footprints of intensive global antibiotic
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use and neglect of typhoid in LMIC (low- and middle-income countries) for more than half a century [3]. Between November 2016 and
December 2019, a total of 15,238 XDR S. Typhi have been reported in
Sindh province (in the south-east of Pakistan) alone [4]. This XDR
outbreak is declared the largest drug-resistant typhoid outbreak
to date. While not the first time, S. Typhi has challenged the global
public health community, the current episode has highlighted the
need for comprehensive typhoid fever prevention measures.
2. Disease burden
Estimates indicate an annual 143 million cases of typhoid and
116,000 deaths [5]. South Asia exhibits 75% of global case count
and the highest age adjusted incidence of 1506 per 100,000 person-years [5]. Globally in 2017, S. Typhi attributed to 8.3 million
years of life lost (YLLs) and 8.4 million disability-adjusted life-years
(DALYs) [5]. Typhoid continues to undermine healthcare systems
in LMIC by inculcating significant health service costs. Increasing
urbanization has contributed to compromised water and sanitation
conditions in cities, and in rural areas, where water and sanitation
conditions remain inadequate. Global climate changes in temperatures, rainfall, and river levels are also contributing to increases in
typhoid cases [6].
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80% of the districts should have 80% completion rates for vaccines
in the immunization schedule. The mathematical models on
typhoid vaccine effectiveness have shown highest impact at least
80% TCV coverage. However, adherence to timely receipt of the
TCV will be imperative as Pakistan and other LMIC continue to
lag behind international benchmarks for completion of current
EPI vaccines [15]. To address this issue proven effective strategies
must be employed to gain stakeholders’ confidence. Vaccine introduction is an iterative process which is both resource- and timeconsuming. Advocacy and communication across a broad range
of stakeholders is essential – not just prior to introduction but
throughout the entire implementation process. With the risks for
increasing mortality and morbidity from multi-drug resistant
typhoid fever, now is the time for a global and local synergy to
ensure adoption, implementation, and sustainability of comprehensive and integrated WASH and TCV programs [16].

3. Typhoid fever and vaccination
Many LMIC do not have the resources and infrastructure to
adopt and sustain water, sanitation, and hygiene (WASH) interventions. In conjunction with continued WASH programs, vaccine
introduction is the most cost-effective public health measure to
decrease the global burden of typhoid fever [7]. While typhoid
fever has recently received attention due to multi-drug resistance,
its concentration in LMICs and associated health, social, and economic burden have not been adequately acknowledged. A farreaching global policy for implementation of vaccines in health
systems is imperative to counteract the emergence of drug resistant S. typhi. Vaccine introduction will not only have a primary
effect of reducing the incidence of Typhoid fever, it will also have
a secondary effect through reduced empiric antibiotic treatment
use and hence development of antimicrobial resistance [8]. Previous programs identified paucity of global policy, fragile health systems, and inadequate planning, funding, and decision-making
procedures as the principal impediments to vaccine introduction
[9]. Furthermore, a scan of WHO-UNICEF immunization uptake
data for Pakistan indicates varying uptake levels less than 80%
for many childhood vaccines [10]. As with the Pakistan’s polio
eradication program, an effective and sustainable TCV immunization program needs efforts to increase public and health sector
engagement of the public and opinion leaders, innovative
immunization program outreach strategies, public health case
finding, promoting antibiotic stewardship, strengthened laboratory
capacity and effective surveillance of vaccine safety and typhoid
disease, to be able to evaluate the program, identify gaps and
address deficiencies [11]. The multilateral organizations (e.g.,
GAVI, WHO) were only willing to invest in a conjugate vaccine,
and international and national stakeholders only saw solution in
WASH interventions. Investment by industry for improved diagnostics to support early detection did not yield a test that can
address the delayed recognition of typhoid. The WHO recommendation of programmatic inclusion of typhoid vaccines (parenteral
unconjugated Vi polysaccharide (ViPS) and oral live attenuated
Ty21a) in high-risk countries was never implemented at scale
[12]. Challenges in public health adoption of ty21a and ViPS were
low levels of efficacy in younger children, repeat dose requirements, and vaccine costs. However, the global political commitment was the main reason since vaccines with similar obstacles
for other diseases have been introduced in routine immunization
programs. These challenges with typhoid fever vaccines could have
been addressed if national support for vaccination and global
financing was available.
More recently, the WHO Strategic Advisory Group of Experts
(SAGE) recommended typhoid conjugate vaccines (TCV) and their
inclusion in routine immunization programs. In the past two decades there are at least six TCV candidates at different development
stages [13]. WHO has prequalified the ViPS tetanus-toxoid conjugate vaccine (Typbar-TCVÒ) which is safe for administration from
6 months of age and has high tolerability [14]. However, despite
the prequalification of TCV, the increasing global drug resistant S.
Typhi strains would require a larger number of TCV supply and
manufacturer capacity in meeting the demand.
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4. The future typhoid control
With the introduction of TCV into Pakistan’s Expanded Program
for Immunization (EPI) in 2019, doors have been opened for introduction in other endemic countries. The WHO recommends that
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